The UCI DMA &Protein MicroArray Facility was initially established in 1999 as a Comprehensive Cancer Center Shared Resource Core Facility, directed at assisting both North and South Campus investigators performing microarray expression analysis. About 200 investigators inside and outside the South Campus have been provided services in the last five year period. We primarily utilize the Affymetrix GeneChip array system to monitor gene expression and perform SNP/genotype mapping. Our mission is to provide RNA expression and genomic DMA analysis in a consistent and timely manner that is of the highest quality for all of our Facility's users. In addition to providing experimental expertise for performing gene expression and SNP/genotype mapping protocols, the staff provides advice and consultation on experimental design, and data analysis approaches and statistics for microarray based research. Currently, the primary use of this technology is to determine the differential expression patterns of genes, either within cells or tissues. This technology enables investigators to compare patterns of expression in diseased and normal cells, cancer cells and non-cancerous cells and in different tissue types. The goal of these types of studies is to better understand the processes that potentially lead to diseased states and to find new or better ways of either controlling or stopping the progression of diseased states. A rapidly increasing use of this technology is analysis of genotypic variants (SNPs) to map disease-causing genes. These types of approaches will provide insight into multifactorial disease states. Genomewide information unlike individual gene information can be used to understand the more subtle patterns of diseases caused by multiple genes or by the confluence of environmental and genetic factors. Because of the great amount of detailed information provided from genomewide arrays, it is likely that microarrays will become an even more important tool not only in understanding disease processes, but also in disease diagnosis and the design of individualized therapies.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of California Irvine
United States
Zip Code
Rush, Christina L; Darling, Margaret; Elliott, Maria Gloria et al. (2015) Engaging Latina cancer survivors, their caregivers, and community partners in a randomized controlled trial: Nueva Vida intervention. Qual Life Res 24:1107-18
Parihar, Vipan K; Allen, Barrett D; Tran, Katherine K et al. (2015) Targeted overexpression of mitochondrial catalase prevents radiation-induced cognitive dysfunction. Antioxid Redox Signal 22:78-91
Stockler, Martin R; Hilpert, Felix; Friedlander, Michael et al. (2014) Patient-reported outcome results from the open-label phase III AURELIA trial evaluating bevacizumab-containing therapy for platinum-resistant ovarian cancer. J Clin Oncol 32:1309-16
Sun, Peng; Watanabe, Kazuhide; Fallahi, Magid et al. (2014) Pygo2 regulates ?-catenin-induced activation of hair follicle stem/progenitor cells and skin hyperplasia. Proc Natl Acad Sci U S A 111:10215-20
Lackford, Brad; Yao, Chengguo; Charles, Georgette M et al. (2014) Fip1 regulates mRNA alternative polyadenylation to promote stem cell self-renewal. EMBO J 33:878-89
Balu, Mihaela; Kelly, Kristen M; Zachary, Christopher B et al. (2014) Distinguishing between benign and malignant melanocytic nevi by in vivo multiphoton microscopy. Cancer Res 74:2688-97
Yonova, Ivelina M; Osborne, Charlotte A; Morrissette, Naomi S et al. (2014) Diaryl and heteroaryl sulfides: synthesis via sulfenyl chlorides and evaluation as selective anti-breast-cancer agents. J Org Chem 79:1947-53
Watanabe, K; Fallahi, M; Dai, X (2014) Chromatin effector Pygo2 regulates mammary tumor initiation and heterogeneity in MMTV-Wnt1 mice. Oncogene 33:632-42
Kim, Monica Y; Li, David Jiang; Pham, Long K et al. (2014) Microfabrication of High-Resolution Porous Membranes for Cell Culture. J Memb Sci 452:460-469
Cheng, Chunmei; Pal, Sukumar; Tifrea, Delia et al. (2014) A vaccine formulated with a combination of TLR-2 and TLR-9 adjuvants and the recombinant major outer membrane protein elicits a robust immune response and significant protection against a Chlamydia muridarum challenge. Microbes Infect 16:244-52

Showing the most recent 10 out of 289 publications